Aurobindo Pharma’s Eugia facility receives OAI classification from US FDA

Business Desk — Sun, 24 May 2026 12:08:34 +0000

Aurobindo Pharma has announced that its wholly owned subsidiary, Eugia Pharma Specialities Ltd., has received an ‘official action indicated’ (OAI) classification from the US Food and Drug Administration (US FDA) for its Unit-I facility in Shameerpet, Telangana. The OAI classification follows an inspection conducted by the US FDA from February 16 to February 27, 2026, which concluded with four observations.

The OAI status indicates that the US FDA has identified issues that may warrant regulatory action. Aurobindo Pharma has stated that there is no impact on its financials or operations due to this classification. The company emphasised its commitment to maintaining high-quality manufacturing standards across all its facilities globally.

The US FDA’s inspection and subsequent classification are part of its regulatory oversight to ensure compliance with manufacturing practices. Aurobindo Pharma has assured that it will keep the stock exchanges informed of any further developments related to this matter.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Shameerpet | Business Upturn

Aurobindo Pharma’s Eugia facility receives OAI classification from US FDA